Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that new preclinical data evaluating oral elraglusib will be presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20, 2026, in Barcelona, Spain.

The study evaluated Elraglusib Oral Tablet as a single agent in the B16F10 syngeneic melanoma model, a poorly immunogenic, rapidly growing and highly aggressive tumor model. Daily oral administration of elraglusib significantly inhibited tumor growth and demonstrated favorable tolerability. Tumor immunophenotyping demonstrated that elraglusib treatment increased the accumulation of CD8+ T cells and natural killer (NK) cells within tumors while decreasing myeloid-like tumor suppressor cells (Ly6G+ neutrophil/PMN-MDSC-like) associated with an immunosuppressive tumor microenvironment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.